18F-FDG PET/CT can be used to detect non-functioning pancreatic neuroendocrine tumors

Luo,Guopei; Liu,Zuqiang; Guo,Meng; Jin,Kaizhou; Xiao,Zhiwen; Liu,Liang; Xu,Jin; Zhang,Bo; Liu,Chen; Huang,Dan; Hu,Silong; Ni,Quanxing; Long,Jiang; Yu,Xianjun

doi:10.3892/ijo.2014.2570

18F-FDG PET/CT can be used to detect non-functioning pancreatic neuroendocrine tumors

Authors:
- Guopei Luo
- Zuqiang Liu
- Meng Guo
- Kaizhou Jin
- Zhiwen Xiao
- Liang Liu
- Jin Xu
- Bo Zhang
- Chen Liu
- Dan Huang
- Silong Hu
- Quanxing Ni
- Jiang Long
- Xianjun Yu
View Affiliations

Affiliations: Department of Pancreatic and Hepatobiliary Surgery, Shanghai Cancer Center, Fudan University, Shanghai 200032, P.R. China, Department of Pathology, Shanghai Cancer Center, Fudan University, Shanghai 200032, P.R. China, Department of Nuclear Medicine, Shanghai Cancer Center, Fudan University, Shanghai 200032, P.R. China
Published online on: July 29, 2014 https://doi.org/10.3892/ijo.2014.2570
Pages: 1531-1536

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

18F-Fluorodeoxyglucose positron emission tomo-graphy and computed tomography (18F-FDG PET/CT) has limited value in well-differentiated neuroendocrine tumors. The value of 18F-FDG PET/CT in non-functioning pancreatic neuroendocrine tumors, which are often poorly differentiated, malignant, and present at an advanced stage, was also thought to be limited. This study was performed to evaluate the clinical value of 18F-FDG PET/CT in assessing non-functioning pancreatic neuroendocrine tumors. From January 2010 to February 2014, a comparable large cohort of patients (31 cases) with non-functioning pancreatic neuroendocrine tumors from Shanghai Cancer Center underwent 18F-FDG PET/CT scans. Demographics and clinical characteristics were retrospectively collected and analyzed for all the patients. Twenty-eight of 31 (90.3%) patients with non-functioning endocrine pancreatic tumors had an elevated 18F-FDG uptake (SUVmax ≥2.5). In addition, 18F-FDG PET/CT visualized 38 of 42 (90.5%) distant metastatic lesions. The 18F-FDG uptake had significant association with tumor size (P=0.012) and TNM stage (P=0.004). The application of 18F-FDG PET/CT has changed the management of 8 cases (8/31, 25.8%). In conclusion, 18F‑FDG PET/CT plays an important role in detecting and staging non-functioning pancreatic neuroendocrine tumors.

View Figures

View References

1	Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, et al: Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol. 21:1794–1803. 2010. View Article : Google Scholar
2	Modlin IM, Oberg K, Chung DC, et al: Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 9:61–72. 2008. View Article : Google Scholar
3	Halfdanarson TR, Rabe KG, Rubin J and Petersen GM: Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 19:1727–1733. 2008. View Article : Google Scholar : PubMed/NCBI
4	Burns WR and Edil BH: Neuroendocrine pancreatic tumors: guidelines for management and update. Curr Treat Options Oncol. 13:24–34. 2012. View Article : Google Scholar : PubMed/NCBI
5	Bertani E, Fazio N, Botteri E, et al: Resection of the primary pancreatic neuroendocrine tumor in patients with unresectable liver metastases: possible indications for a multimodal approach. Surgery. 155:607–614. 2014. View Article : Google Scholar
6	Nomura N, Fujii T, Kanazumi N, et al: Nonfunctioning neuroendocrine pancreatic tumors: our experience and management. J Hepatobiliary Pancreat Surg. 16:639–647. 2009. View Article : Google Scholar : PubMed/NCBI
7	Li J, Luo G, Fu D, et al: Preoperative diagnosis of nonfunctioning pancreatic neuroendocrine tumors. Med Oncol. 28:1027–1031. 2011. View Article : Google Scholar : PubMed/NCBI
8	Czernin J, Weber WA and Herschman HR: Molecular imaging in the development of cancer therapeutics. Annu Rev Med. 57:99–118. 2006. View Article : Google Scholar
9	von Schulthess GK, Steinert HC and Hany TF: Integrated PET/CT: current applications and future directions. Radiology. 238:405–422. 2006.PubMed/NCBI
10	Adams S, Baum R, Rink T, Schumm-Drager PM, Usadel KH and Hor G: Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med. 25:79–83. 1998. View Article : Google Scholar : PubMed/NCBI
11	Slooter GD, Mearadji A, Breeman WA, et al: Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours. Br J Surg. 88:31–40. 2001. View Article : Google Scholar : PubMed/NCBI
12	Binderup T, Knigge U, Loft A, et al: Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, ¹²³I-MIBG scintigraphy, and ¹⁸F-FDG PET. J Nucl Med. 51:704–712. 2010. View Article : Google Scholar : PubMed/NCBI
13	Kayani I, Bomanji JB, Groves A, et al: Functional imaging of neuroendocrine tumors with combined PET/CT using ⁶⁸Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and ¹⁸F-FDG. Cancer. 112:2447–2455. 2008. View Article : Google Scholar : PubMed/NCBI
14	Modlin IM, Pavel M, Kidd M and Gustafsson BI: Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther. 31:169–188. 2010.PubMed/NCBI
15	National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Pancreatic Endocrine Tumors. 2:14–18. 2014.
16	Naswa N, Sharma P, Kumar A, et al: Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study. AJR Am J Roentgenol. 197:1221–1228. 2011. View Article : Google Scholar : PubMed/NCBI
17	Kisker O, Bartsch D, Weinel RJ, et al: The value of somatostatin-receptor scintigraphy in newly diagnosed endocrine gastroenteropancreatic tumors. J Am Coll Surg. 184:487–492. 1997.PubMed/NCBI
18	Rickes S, Unkrodt K, Ocran K, Neye H and Wermke W: Differentiation of neuroendocrine tumors from other pancreatic lesions by echo-enhanced power Doppler sonography and somatostatin receptor scintigraphy. Pancreas. 26:76–81. 2003. View Article : Google Scholar
19	Pasquali C, Rubello D, Sperti C, et al: Neuroendocrine tumor imaging: can ¹⁸F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior? World J Surg. 22:588–592. 1998.PubMed/NCBI
20	Strauss LG and Conti PS: The applications of PET in clinical oncology. J Nucl Med. 32:623–650. 1991.PubMed/NCBI
21	Gabriel M, Decristoforo C, Kendler D, et al: ⁶⁸Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 48:508–518. 2007. View Article : Google Scholar
22	Ambrosini V, Tomassetti P, Castellucci P, et al: Comparison between ⁶⁸Ga-DOTA-NOC and ¹⁸F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging. 35:1431–1438. 2008.
23	Orlefors H, Sundin A, Garske U, et al: Whole-body (11) C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab. 90:3392–3400. 2005. View Article : Google Scholar